FIGURE 1.

Proteins up-regulated proteins in psoriasis serum at baseline and down-regulated after 12 weeks of ustekinumab treatment. Serum samples from 10 psoriasis patients at baseline and after 12 weeks of ustekinumab treatment, and from 18 healthy controls were analysed for 276 protein concentrations using three panels (Cardiovascular II, Cardiovascular III and Inflammation) from the Olink high-throughput multiplex assay. Protein expression profiles were estimated under limma package framework using mixed-effect linear models. Fold changes (FCH) for condition (baseline/control) and timepoint (baseline/posttreatment Week 12) were calculated. Proteins were defined as differentially expressed if the average value in psoriasis serum was an increase or decrease relative to control with a p-value ≤0.1. Left: 49 proteins were up-regulated in psoriasis patients at baseline (p ≤ 0.1). Right: 43 proteins were down-regulated after 12 weeks of ustekinumab treatment (p ≤ 0.1). Middle: 25 proteins were up-regulated at baseline and down-regulated after treatment. *indicates modulation of IL-12B could not be assessed due to ustekinumab’s interference with the IL-12p40 subunit